Breast cancer

Mammography
#Breast cancer #Cancer research #European Commission #Gene mutation #Genetics / genomes #HER2 #Oncology

Drug approved for breast cancer with low levels of HER2 expression

Enhertu has been approved in the EU as the first HER2 directed therapy for patients with HER2 low metastatic breast cancer.  The drug is approved as monotherapy for adult patients who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six… Read More

#Cancer Research #Editor's Choice #News

Patient using a mammography machine
#AstraZeneca #Breast cancer #Cancer research #Phase III trial #Precision medicine #The Institute of Cancer Research

Targeted breast cancer drug extends lives of patients in Phase III trial

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major Phase III clinical trial.  The drug capivasertib combined with hormone therapy doubled the time it took for cancer to progress in people with advanced forms of the most… Read More

#Cancer Research #News #Trending News

Wear it Pink
#Breast cancer #Breast Cancer Now #Cancer research #Chemotherapy #Chemotherapy-resistance #Drug discovery #Oncology #Tumours

Five breakthroughs advancing breast cancer therapies

Not only is October Breast Cancer Awareness Month but October 21 is Wear it Pink 2022, Breast Cancer Now’s annual fundraising day. While advances in treatment over the last few years have resulted in good overall survival rates for patients with non-metastatic disease (90% five-year survival rate in the US1),… Read More

#Cancer Research #News #Trending News

Breast cancer
#Breast cancer #Breast Cancer Now #Cancer immunotherapy #Cancer research #King's College London #Oncology #The Institute of Cancer Research

Immune targets identified for chemo-resistant breast cancers

Researchers from King’s College London and The Institute of Cancer Research, London, have performed a deep dive into the different immune markers within tumour tissue and blood samples of early breast cancer patients whose cancer failed to respond to chemotherapy given to them prior to surgery. The research gives insight… Read More

#Cancer Research #News

#ALS #Alzheimer's #Biomarkers #Breast cancer #Cell and gene therapy #Head and neck cancer #Ice Bucket Challenge #Manufacturing #Neurodegenerative disorders #Oncology #Ophthalmology

This week in drug discovery (3-7 October)

News round-up for 3-7 October by DDW Digital Content Editor Diana Spencer This week has brought new trial results and regulatory approvals shedding light and bringing hope into therapy areas of unmet need. The University of Birmingham and… Read More

#News

Breast cancer cells
#Breast cancer #Cancer research #Oncology

Breast cancer cells ‘regulate their own metastases’

Scientists have discovered a type of breast cancer cell that is highly efficient in invading and colonising distant organs and slow their growth once there to evade therapies. This phenomenon then leads to later metastatic breast cancer in patients who have been cancer-free for years. According to a study published… Read More

#Cancer Research #News

#Breast cancer #Drug discovery #Oncology

Nitric oxide could form treatment approach for breast cancer

A new therapeutic approach for triple negative breast cancer using nitric oxide is being explored by researchers at the medical research centre CÚRAM. Amir Abdo Alsharabasy, a CÚRAM doctoral candidate working in the laboratory of Professor Abhay Pandit, is working on the design of nitric oxide scavengers to form a… Read More

#News

#AstraZeneca #Breast cancer #Institute of Cancer Research #Oncology

EMA approves early-stage breast cancer treatment  

A precision medicine for early-stage breast cancer has been approved by the European Medicines Agency (EMA).   Developed by AstraZeneca and Merck & Co (MSD) under the brand name Lynparza, the treatment is a precision medicine which blocks DNA damage response (DDR) in cells or tumours that have… Read More

#Cancer Research #News

Mammography
#Breast cancer #Eli Lilly #Oncology

UK’s NICE recommends Eli Lilly’s breast cancer drug  

Early breast cancer patients in England will be able to access a new form of treatment following the recommendation for Eli Lilly’s abemaciclib by the National Institute of Health and Care Excellence (NICE).  The approval means that abemaciclib will be able to be used in combination with… Read More

#News